ArticleJournal of pharmaceutical health care and sciences2026
Factors associated with peripheral neuropathy development during gemcitabine plus albumin-bound paclitaxel therapy as first-line treatment for unresectable pancreatic cancer: a retrospective evaluation.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine plus albumin-bound paclitaxel is widely used as first-line therapy for unresectable pancreatic cancer, but it is frequently complicated by chemotherapy-induced peripheral neuropathy, which may lead to functional impairment and treatment modification. Factors associated with clinically relevant neuropathy, defined as grade 2 or higher, remain insufficiently clarified. This study aimed to identify factors associated with the development of grade ≥ 2 neuropathy during therapy.
methodsWe conducted a retrospective observational study using medical records of patients with unresectable pancreatic cancer who received this combination therapy at Rakuwakai Otowa Hospital from April 2015 to March 2024. Patient characteristics, treatment details, and neuropathy outcomes were collected. Univariate and multivariate logistic regression analyses were performed to evaluate factors associated with grade ≥ 2 neuropathy. Statistical significance was defined as P < 0.05.
resultsFifty-seven patients were included in the analysis, and 19 patients (33.3%) developed grade ≥ 2 neuropathy. In multivariate logistic regression, a history of diabetes mellitus was significantly associated with the development of grade ≥ 2 neuropathy (odds ratio 3.89, 95% confidence interval 1.06–14.3, P = 0.041). No other clinical or treatment-related variables demonstrated significant associations.
conclusionsA history of diabetes mellitus may be associated with the development of grade ≥ 2 CIPN in patients with unresectable pancreatic cancer undergoing GnP therapy. Healthcare professionals should detect CIPN symptoms early and manage them appropriately, particularly in patients with diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.